In Vitro Efficacy of Ceftazidime-Avibactam on Carbapenem-Resistant Pseudomonas aeruginosa Isolates
Abstract
Pseudomonas aeruginosa is the main Pseudomonas species causing hospital infections. Ceftazidime-avibactam (CZA) is a new beta-lactam/beta-lactamase inhibitor combination effective against carbapenem-resistant P. aeruginosa isolates. The aim of this study was to evaluate the in vitro activity of CZA against carbapenem-resistant P. aeruginosa isolates. In hospitalized patient culture samples, 190 isolates that were evaluated as significant growth and identified as P. aeruginosa with the Vitek 2 Compact automated system (BioMérieux, France) and determined as imipenem resistant (≥ 8 mg/L) and meropenem resistant (≥ 16 mg/L)with the same system were included in the study. 88% (167/190) of P. aeruginosa strains were isolated from patients in intensive care units and 78% (148/190) from respiratory tract samples. CZA activity was studied with disk diffusion test (10-4 µg disk) and zone diameters <17 mm were accepted as resistant. 20% (38/190) of the isolates were found to be resistant to CZA. The difference in resistance rates between CZA and all of the studied antimicrobials except amikacin is highly significant (p: 0.006 - <0.001). The low resistance rate found in our study indicates that CZA is a good option for the treatment of carbapenem-resistant P. aeruginosa isolates. In addition, amikacin treatment with a low resistance rate may be an appropriate approach for patients requiring combination therapy. The increasing problem of carbapenem resistance and multidrug resistance requires more studies to evaluate the effectiveness of new antimicrobials and drug combinations.
Keywords
pseudomonas aeruginosa , ceftazidime-avibactam , carbapenem resistance
References
- Daikos GL, da Cunha CA, Rossolini GM, Stone, G.G et al. Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa. Antibiotics, 2021;10(9):1126.
- Hancock RE, Speert DP. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and impact on treatment. Drug Resistance Updates, 2000; 3: 247-255.
- Shortridge D, Gales AC, Streit JM, Huband MD et al. Geographic and temporal patterns of antimicrobial resistance in pseudomonas aeruginosa over 20 years from the SENTRY Antimicrobial Surveillance Program, 1997-2016. Open Forum Infect Dis 2019;6(Suppl 1):S63-S68.
- Shrivastava SR, Shrivastava PS, Ramasamy J. World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. JMS- Journal of Medical Society, 2018; 32: 76-77.
- Yin, S., Chen, P., You, B., Zhang, Y et al. Molecular typing and carbapenem resistance mechanisms of Pseudomonas aeruginosa isolated from a Chinese burn center from 2011 to 2016. Frontiers in Microbiology, 2018; 9.
- Herrero FS. Ceftazidime-avibactam. Revista Espanola de Quimioterapia 2022; 35: 40-42.
- Soriano A, Carmeli Y, Omrani AS, Moore LSP et al. Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. Infect Dis Ther 2021; 10: 1989-2034.
- The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, 2022. http://www.eucast.org [erişim tarihi: 19.10.2022]
- Dalfino L, Puntillo F, Ondok MJM, Mosca A et al. Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study. Clinical Infectious Diseases 2015; 61: 1771-1777.
- Sternbach N, Weissman YL, Avni T, Yahav D. Efficacy and safety of ceftazidime/avibactam: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy 2018; 73: 2021-2029.